Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemic cardiac events

Julia F. Shaklee; Thomas R. Talbot; James A S Muldowney; Douglas E. Vaughan; Javed Butler; Frances House; James E. Crowe; L. Harris Smith; Kathryn M. Edwards

doi:10.1086/427831

Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemic cardiac events

Julia F. Shaklee, Thomas R. Talbot^*, James A S Muldowney, Douglas E. Vaughan, Javed Butler, Frances House, James E. Crowe, L. Harris Smith, Kathryn M. Edwards

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background. During the recent smallpox vaccination campaigns, ischemic cardiac complications were observed after vaccination. To examine a possible association between the smallpox vaccine and postvaccination ischemic events, we investigated alterations in levels of prothrombotic proteins (plasminogen activator inhibitor type 1 [PAI-1] and soluble CD40 ligand [sCD40L]) in recently vaccinated individuals. Methods. Vaccinia-naive (cohort N; aged 18-32 years) and vaccinia-experienced (cohort E; aged 33-49 years) healthy adults were vaccinated with a 1:5 dilution of the Aventis Pasteur smallpox vaccine. Plasma levels of PAI-1 and sCD40L were measured in 30 subjects (cohort N, n = 15; cohort E, n = 15) at baseline and twice after vaccination (between days 7 and 9 and between days 26 and 30). Results. Baseline mean PAI-1 levels significantly differed between cohorts N and E (P = .04). Within each exposure cohort, mean PAI-1 levels did not significantly change after vaccination. Baseline sCD40L levels did not differ between cohorts N and E. In cohort N, sCD40L levels significantly decreased after vaccination but returned to baseline levels within 1 month. Vaccination did not significantly alter levels of sCD40L in cohort E. Conclusions. Levels of PAI-1 and sCD40L did not significantly increase after smallpox vaccination. Vaccine-induced alterations in levels of these prothrombotic proteins do not appear to play a role in ischemic events observed after smallpox vaccination.

Original language	English (US)
Pages (from-to)	724-730
Number of pages	7
Journal	Journal of Infectious Diseases
Volume	191
Issue number	5
DOIs	https://doi.org/10.1086/427831
State	Published - Mar 1 2005

Funding

Financial support: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID) (contract N01-AI-25462); General Clinical Research Center (grant M01-RR-00095); National Institutes of Health/ NIAID (grant RO1-AI-57661 to J.E.C.); Stanley J. Sarnoff Endowment for Cardiovascular Science (support to J.A.S.M.).

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/427831

Cite this

@article{8802eab5433d4edda55c1801916885f3,

title = "Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemic cardiac events",

abstract = "Background. During the recent smallpox vaccination campaigns, ischemic cardiac complications were observed after vaccination. To examine a possible association between the smallpox vaccine and postvaccination ischemic events, we investigated alterations in levels of prothrombotic proteins (plasminogen activator inhibitor type 1 [PAI-1] and soluble CD40 ligand [sCD40L]) in recently vaccinated individuals. Methods. Vaccinia-naive (cohort N; aged 18-32 years) and vaccinia-experienced (cohort E; aged 33-49 years) healthy adults were vaccinated with a 1:5 dilution of the Aventis Pasteur smallpox vaccine. Plasma levels of PAI-1 and sCD40L were measured in 30 subjects (cohort N, n = 15; cohort E, n = 15) at baseline and twice after vaccination (between days 7 and 9 and between days 26 and 30). Results. Baseline mean PAI-1 levels significantly differed between cohorts N and E (P = .04). Within each exposure cohort, mean PAI-1 levels did not significantly change after vaccination. Baseline sCD40L levels did not differ between cohorts N and E. In cohort N, sCD40L levels significantly decreased after vaccination but returned to baseline levels within 1 month. Vaccination did not significantly alter levels of sCD40L in cohort E. Conclusions. Levels of PAI-1 and sCD40L did not significantly increase after smallpox vaccination. Vaccine-induced alterations in levels of these prothrombotic proteins do not appear to play a role in ischemic events observed after smallpox vaccination.",

author = "Shaklee, {Julia F.} and Talbot, {Thomas R.} and Muldowney, {James A S} and Vaughan, {Douglas E.} and Javed Butler and Frances House and Crowe, {James E.} and Smith, {L. Harris} and Edwards, {Kathryn M.}",

note = "Funding Information: Financial support: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID) (contract N01-AI-25462); General Clinical Research Center (grant M01-RR-00095); National Institutes of Health/ NIAID (grant RO1-AI-57661 to J.E.C.); Stanley J. Sarnoff Endowment for Cardiovascular Science (support to J.A.S.M.).",

year = "2005",

month = mar,

day = "1",

doi = "10.1086/427831",

language = "English (US)",

volume = "191",

pages = "724--730",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemic cardiac events

AU - Shaklee, Julia F.

AU - Talbot, Thomas R.

AU - Muldowney, James A S

AU - Vaughan, Douglas E.

AU - Butler, Javed

AU - House, Frances

AU - Crowe, James E.

AU - Smith, L. Harris

AU - Edwards, Kathryn M.

N1 - Funding Information: Financial support: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID) (contract N01-AI-25462); General Clinical Research Center (grant M01-RR-00095); National Institutes of Health/ NIAID (grant RO1-AI-57661 to J.E.C.); Stanley J. Sarnoff Endowment for Cardiovascular Science (support to J.A.S.M.).

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Background. During the recent smallpox vaccination campaigns, ischemic cardiac complications were observed after vaccination. To examine a possible association between the smallpox vaccine and postvaccination ischemic events, we investigated alterations in levels of prothrombotic proteins (plasminogen activator inhibitor type 1 [PAI-1] and soluble CD40 ligand [sCD40L]) in recently vaccinated individuals. Methods. Vaccinia-naive (cohort N; aged 18-32 years) and vaccinia-experienced (cohort E; aged 33-49 years) healthy adults were vaccinated with a 1:5 dilution of the Aventis Pasteur smallpox vaccine. Plasma levels of PAI-1 and sCD40L were measured in 30 subjects (cohort N, n = 15; cohort E, n = 15) at baseline and twice after vaccination (between days 7 and 9 and between days 26 and 30). Results. Baseline mean PAI-1 levels significantly differed between cohorts N and E (P = .04). Within each exposure cohort, mean PAI-1 levels did not significantly change after vaccination. Baseline sCD40L levels did not differ between cohorts N and E. In cohort N, sCD40L levels significantly decreased after vaccination but returned to baseline levels within 1 month. Vaccination did not significantly alter levels of sCD40L in cohort E. Conclusions. Levels of PAI-1 and sCD40L did not significantly increase after smallpox vaccination. Vaccine-induced alterations in levels of these prothrombotic proteins do not appear to play a role in ischemic events observed after smallpox vaccination.

AB - Background. During the recent smallpox vaccination campaigns, ischemic cardiac complications were observed after vaccination. To examine a possible association between the smallpox vaccine and postvaccination ischemic events, we investigated alterations in levels of prothrombotic proteins (plasminogen activator inhibitor type 1 [PAI-1] and soluble CD40 ligand [sCD40L]) in recently vaccinated individuals. Methods. Vaccinia-naive (cohort N; aged 18-32 years) and vaccinia-experienced (cohort E; aged 33-49 years) healthy adults were vaccinated with a 1:5 dilution of the Aventis Pasteur smallpox vaccine. Plasma levels of PAI-1 and sCD40L were measured in 30 subjects (cohort N, n = 15; cohort E, n = 15) at baseline and twice after vaccination (between days 7 and 9 and between days 26 and 30). Results. Baseline mean PAI-1 levels significantly differed between cohorts N and E (P = .04). Within each exposure cohort, mean PAI-1 levels did not significantly change after vaccination. Baseline sCD40L levels did not differ between cohorts N and E. In cohort N, sCD40L levels significantly decreased after vaccination but returned to baseline levels within 1 month. Vaccination did not significantly alter levels of sCD40L in cohort E. Conclusions. Levels of PAI-1 and sCD40L did not significantly increase after smallpox vaccination. Vaccine-induced alterations in levels of these prothrombotic proteins do not appear to play a role in ischemic events observed after smallpox vaccination.

UR - http://www.scopus.com/inward/record.url?scp=13944284438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13944284438&partnerID=8YFLogxK

U2 - 10.1086/427831

DO - 10.1086/427831

M3 - Article

C2 - 15688286

AN - SCOPUS:13944284438

SN - 0022-1899

VL - 191

SP - 724

EP - 730

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 5

ER -

Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemic cardiac events

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this